Nuvation Bio Receives FDA Approval for Updated Treatment Duration of IBTROZI® for ROS1-Positive Lung Cancer #United_States #New_York #Nuvation_Bio #IBTROZI® #ROS1_cancer
@newsen.bsky.social
@newsen.bsky.socialNuvation Bio Receives FDA Approval for Updated Treatment Duration of IBTROZI® for ROS1-Positive Lung Cancer #United_States #New_York #Nuvation_Bio #IBTROZI® #ROS1_cancer
@newsen.bsky.socialNuvation Bio's IBTROZI® Shows Consistent Efficacy in Advanced ROS1+ NSCLC Subgroups at 2026 WCLC #USA #New_York #Lung_Cancer #Nuvation_Bio #IBTROZI